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OBJECTIVES: To project the cumulative incidence of end-stage
renal disease (ESRD), life expectancy and costs in Taiwan of
treating patients with diabetes, hypertension, and microalbu-
minuria (DHM) with either standard hypertension treatment
alone or standard hypertension treatment plus irbesartan 300mg
daily. METHODS: A peer-reviewed, published Markov model
that simulated progression from microalbuminuria to nephropa-
thy, doubling of serum creatinine, ESRD, and all-cause mortal-
ity in patients with DHM was adapted to Taiwan. Three
strategies were compared: A) early use of irbesartan (i.e. start
treatment in subjects with microalbuminuria) versus B) late use
of irebesartan (i.e. as from overt nephropathy), or C) standard
hypertension care (with comparable blood pressure control).
Cumulative incidence of ESRD, costs and life expectancy were
projected for a hypothetical cohort of 1000 subjects. Treatment-
speciﬁc progression and mortality probabilities were derived
from published trials: IRMA-2 (in microalbuminuria) and IDNT
(in overt nephropathy). Medical management and cost data per
state were obtained from published local sources. A ﬂexible time
horizon up to 25-years and third party payer perspective were
used. Future costs and LE were discounted at 3% yearly.
RESULTS: When compared to standard blood pressure control,
early irbesartan was projected to reduce the cumulative incidence
of ESRD from (mean ± standard deviation) 22% to 8%, save
TN $248,302 (US $7303), and add 0.702 life years per treated
patient. Late irbesartan was dominant to control but dominated
by early irbesartan. The superiority of early use of irbesartan
over standard care was robust for most variables, except for the
cost of dialysis and the time horizon. Break-even occurred after
12 years. CONCLUSIONS: Treating DHM patients with early
irbesartan was projected to reduce the incidence of ESRD, extend
life and reduce costs. Treating patients at a later stage is still ben-
eﬁcial, however to a lower extent. Applying ﬂexible time hori-
zons shows additional relevant information to decision makers.
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OBJECTIVES: To determine the number needed to treat (NNT)
for one additional patient to achieve the Joint European Task
Force 1998 goal for low-density lipoprotein cholesterol (LDL-C)
of <3.0mmol/L (116mg/dL) at 6 weeks for rosuvastatin 10mg
compared to atorvastatin, pravastatin and simvastatin. Patients
included in the Statin Therapies for Elevated Lipid Levels com-
pared Across doses to Rosuvastatin (STELLAR) trial had an
initial LDL-C ≥ 4.1mmol/L (160mg/dL) and <6.5mmol/L 
(250mg/dL). METHODS: Data on patients achieving the Euro-
pean 1998 LDL-C goal with rosuvastatin and the other statins
were extracted and recalculated using an intention to treat (ITT)
approach where all patients randomised were included in the
analysis and any dropouts were assumed to be treatment fail-
ures. The ITT analysis formed the basis of the NNT calculations.
Negative NNT’s were interpreted as inﬁnity. RESULTS: The
NNT’s for rosuvastatin 10mg compared to the other statins are:
atorvastatin 10mg (3.9, 95%CI: 2.8 to 6.3), 20mg (9.5, 95%CI:
4.9 to 135.8); 40mg (361.1 in favour of atorvastatin, 
95%CI: 10.7 to inﬁnity); 80mg (17.7 in favour of atorvastatin,
95%CI: 7.2 to inﬁnity); simvastatin 10mg (1.9, 95%CI: 1.6 to
2.3), 20mg (3.1, 95%CI: 2.3 to 4.4); 40mg (6.7, 95%CI: 4.0 to
19.8), 80mg (67.4, 95%CI: 9.4 to inﬁnity); pravastatin 10mg
(1.4, 95%CI: 1.2 to 1.5), 20mg (1.6, 95%CI: 1.4 to 1.8); 40mg
(1.9, 95%CI: 1.6 to 2.4). In applying NNT’s, the numbers should
be rounded up, e.g. an NNT of 3.9 means that you need to treat
4 patients with rosuvastatin 10mg rather than atorvastatin 10
mg to get one additional patient to the LDL-C goal at six weeks.
CONCLUSIONS: NNT’s are the “currency” of EBM with an
NNT < 40 considered beneﬁcial in chronic conditions. In this
context, rosuvastatin 10mg has an advantageous NNT proﬁle
compared to the available doses of other statins.
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Majority of patients treated for hyperlipidemia with available
cholesterol lowering drugs (LLD) do not achieve recommended
LDL-C goal in Spain. OBJECTIVES: To assess LDL-C reduction
and goal attainment over time and determine time period when
patients are most likely to attain goal after initiation of LLD in
Spain. METHODS: Retrospective cohort study conducted at 23
primary care centres and 16 outpatient lipid centres. Eligible
patients were adults (≥18 years) with CHD/CHD equivalent or
2+ major risk factors (2 + RF) prior to ﬁrst prescription of LLD
between January 1998–April 1999, and +36 months of follow-
up data after. LDL-C goals were based on NCEP III guidelines
(100mg/dl for CHD/CHD equivalent patients, 130mg/dl for 2 +
RF group). Goal attainment analyses were based on proportion
of patients at goal from those with a valid LDL-C measure at 3
month time intervals from therapy start, and on increase or
decrease in that proportion for subsequent periods. RESULTS:
A total of 619 patients (46% CHD/CHD equivalent and 54%
nonCHD with 2 + RFs) were included in the study. Mean age
was 60 years (SD 10.22), 48% were female. Statins were initial
LLD in 90% patients. Only 20% CHD and 29% 2 + RF patients
were at goal at study end. Proportion of patients at goal
increased to 23% after 3 months of therapy start and remained
stable afterwards around 25%. Increase in proportion of patients
at goal was only positive (+23%) for the ﬁrst 3 months (p < 0.05)
and then remained around 0% increase till study end. CON-
CLUSIONS: Percentage of patients at goal only increased during
ﬁrst three month period after start of lipid lowering therapy,
remaining ﬂat there-after. More aggressive lipid lowering therapy
should be started for those not at goal after ﬁrst 3 months from
LLD start, to enable more patients to get to LDL-C goal.
